Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Feasibility of Day-surgery Management for Patients Undergoing Robotic Radical Prostatectomy: a Randomized Trial

NCT06891664 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-10-23
Last updated
2026-06-05

Condition(s) studied

Prostate Cancer

Investigational drug(s) / intervention(s)

Day surgery regimen for patientsOrdinary management

Day surgery regimen for patients: The protocol includes admission on the evening of Day -1 and the execution of the surgery on the morning of Day 0 under general anesthesia. The surgery will be performed with the aid of the Da Vinci Single-port robotic system with extraperitoneal access.

Ordinary management: Management of patients undergoing robotic radical prostatectomy in an inpatient setting based on a minimum of two nights of hospitalization

Study summary

To compare the day-surgery approach versus routine management in patients undergoing robotic radical prostatectomy, aimed at evaluating the feasibility of a one-day hospitalization regimen for robotic radical prostatectomy.

The study will allow to evaluate the patients'compliance and subsequently investigate the safety, the impact on the patient's quality of life and on the healthcare costs resulting from day-surgery management of patients undergoing robotic radical prostatectomy.

Eligibility

Sex
MALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * patients with localized prostate adenocarcinoma at low-intermediate risk (EAU Risk classification); * patients aged \>= 18 years; * patients with an indication to undergo robotic radical prostatectomy without lymphadenectomy according to the EAU guidelines; * patients who agree to undergo robotic radical prostatectomy without lymphadenectomy according to the EAU guidelines by signing a written informed consent; * patients eligible for robotic radical prostatectomy without lymphadenectomy and in the absence of contraindications to undergo the procedure; * patient's ability to understand and willingness to sign a written informed consent indicating that he has understood the purpose and methods of conducting the study and is interested in participating.; * patients able to follow the indications specified in the study protocol; * patients domiciled (even temporarily) \< 150 km away from the institution where the procedure will be performed; * patients domiciled (even temporarily) \< 60 minutes by car from a reference Emergency and Acceptance Department (DEA). Exclusion Criteria: * patients \> 75 years of age; * ASA \> 2; * second simultaneous surgery; * prostate volume \> 80 cc estimated on preoperative imaging (transrectal ultrasound or magnetic resonance imaging); * patients receiving anticoagulants or oral antiplatelet drugs; * other concomitant tumors undergoing treatment; * previous pelvic radiotherapy; * previous surgery for benign prostatic hypertrophy; * patients lacking the digital literacy required to take advantage of telemedicine intervention; * patients who cannot benefit from at least one caregiver; * patients not suitable for a day-surgery approach based on the clinical evaluation of the operating surgeons and anesthetists.

Primary outcome measure(s)

  • Study enrollment rate among eligible patients. — 30 months
    RCT (randomized controlled trial) enrollment measured as the relative frequency percentage of patients who meet the eligibility criteria and agree to participate in the proposed trial (numerator), divided by the number of all eligible patients in the recruitment period (denominator). Patients who withdraw consent before knowing the outcome of randomization will be counted as having refused participation. The expected result is an enrollment rate of at least 30%. Therefore, the primary objective will be considered achieved if at least 30% of eligible patients agree to participate in the aforementioned trial

Trial sites (1)

FacilityCityRegionStatus
"Regina Elena" National Cancer Institute Rome Rome
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06891664 on ClinicalTrials.gov ↗ ← All trials in Italy